Blog

Home  /  News   /  EUnetHTA joint rapid assessment on sorafenib (Nexavar®) and its use as a treatment of thyroid carcinoma

EUnetHTA joint rapid assessment on sorafenib (Nexavar®) and its use as a treatment of thyroid carcinoma

The joint rapid assessment of WP5 Strand A evaluates ‘sorafenib for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma refractory to radioactive iodine’ is available.

Find the joint rapid assessment here.